Suppr超能文献

相似文献

1
Identification of protein phosphatase 1 as a regulator of the LRRK2 phosphorylation cycle.
Biochem J. 2013 Nov 15;456(1):119-28. doi: 10.1042/BJ20121772.
2
Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2.
Nat Chem Biol. 2011 Apr;7(4):203-5. doi: 10.1038/nchembio.538. Epub 2011 Mar 6.
3
Protein phosphatase 2A holoenzymes regulate leucine-rich repeat kinase 2 phosphorylation and accumulation.
Neurobiol Dis. 2021 Sep;157:105426. doi: 10.1016/j.nbd.2021.105426. Epub 2021 Jun 16.
4
Phosphorylation of LRRK2 serines 955 and 973 is disrupted by Parkinson's disease mutations and LRRK2 pharmacological inhibition.
J Neurochem. 2012 Jan;120(1):37-45. doi: 10.1111/j.1471-4159.2011.07537.x. Epub 2011 Nov 11.
7
LRRK2 dephosphorylation increases its ubiquitination.
Biochem J. 2015 Jul 1;469(1):107-20. doi: 10.1042/BJ20141305. Epub 2015 May 5.
8
Characterization of TAE684 as a potent LRRK2 kinase inhibitor.
Bioorg Med Chem Lett. 2012 Mar 1;22(5):1864-9. doi: 10.1016/j.bmcl.2012.01.084. Epub 2012 Jan 28.
9
LRRK2 GTPase dysfunction in the pathogenesis of Parkinson's disease.
Biochem Soc Trans. 2012 Oct;40(5):1074-9. doi: 10.1042/BST20120093.

引用本文的文献

1
14-3-3 binding maintains the Parkinson's associated kinase LRRK2 in an inactive state.
Nat Commun. 2025 Aug 5;16(1):7226. doi: 10.1038/s41467-025-62337-1.
2
Leucine-rich repeat kinase 2 biomarkers for Parkinson's disease.
Biochem J. 2025 May 28;482(11):BCJ20253099. doi: 10.1042/BCJ20253099.
3
G2019S selective LRRK2 kinase inhibitor abrogates mitochondrial DNA damage.
NPJ Parkinsons Dis. 2024 Mar 1;10(1):49. doi: 10.1038/s41531-024-00660-y.
4
Post-translational modification and mitochondrial function in Parkinson's disease.
Front Mol Neurosci. 2024 Jan 11;16:1329554. doi: 10.3389/fnmol.2023.1329554. eCollection 2023.
5
PAK6-mediated phosphorylation of PPP2R2C regulates LRRK2-PP2A complex formation.
Front Mol Neurosci. 2023 Dec 18;16:1269387. doi: 10.3389/fnmol.2023.1269387. eCollection 2023.
7
Leucine-rich repeat kinase 2 at a glance.
J Cell Sci. 2023 Sep 1;136(17). doi: 10.1242/jcs.259724. Epub 2023 Sep 12.
8
Overview of the Impact of Pathogenic LRRK2 Mutations in Parkinson's Disease.
Biomolecules. 2023 May 16;13(5):845. doi: 10.3390/biom13050845.
9
Impact of Type II LRRK2 inhibitors on signaling and mitophagy.
Biochem J. 2021 Oct 15;478(19):3555-3573. doi: 10.1042/BCJ20210375.
10
Abrogation of LRRK2 dependent Rab10 phosphorylation with TLR4 activation and alterations in evoked cytokine release in immune cells.
Neurochem Int. 2021 Jul;147:105070. doi: 10.1016/j.neuint.2021.105070. Epub 2021 May 15.

本文引用的文献

1
Phosphorylation of LRRK2: from kinase to substrate.
Biochem Soc Trans. 2012 Oct;40(5):1102-10. doi: 10.1042/BST20120128.
2
Screening for novel LRRK2 inhibitors using a high-throughput TR-FRET cellular assay for LRRK2 Ser935 phosphorylation.
PLoS One. 2012;7(8):e43580. doi: 10.1371/journal.pone.0043580. Epub 2012 Aug 28.
5
Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: The PDGene database.
PLoS Genet. 2012;8(3):e1002548. doi: 10.1371/journal.pgen.1002548. Epub 2012 Mar 15.
6
LRRK2 Parkinson disease mutations enhance its microtubule association.
Hum Mol Genet. 2012 Feb 15;21(4):890-9. doi: 10.1093/hmg/ddr526. Epub 2011 Nov 11.
7
What genetics tells us about the causes and mechanisms of Parkinson's disease.
Physiol Rev. 2011 Oct;91(4):1161-218. doi: 10.1152/physrev.00022.2010.
8
Phosphorylation of LRRK2 serines 955 and 973 is disrupted by Parkinson's disease mutations and LRRK2 pharmacological inhibition.
J Neurochem. 2012 Jan;120(1):37-45. doi: 10.1111/j.1471-4159.2011.07537.x. Epub 2011 Nov 11.
10
Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study.
Lancet Neurol. 2011 Oct;10(10):898-908. doi: 10.1016/S1474-4422(11)70175-2. Epub 2011 Aug 30.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验